---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-279091"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:17:02.427541+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q3 cash $225.7M; UK/EU approval for FT819; first SSc patient treated

## Summary
- Cash, cash equivalents & investments $225.7M; projected runway through year-end 2027.
- Total revenue $1.7M from Ono collaboration; operating expenses $36.5M incl. $4.9M SBC.
- Received UK MHRA and EU EMA authorization to activate ex-US sites for FT819 in autoimmune disease.
- First systemic sclerosis patient treated in Phase 1 with fludarabine-free conditioning; no notable AEs.
- First patient (stage IV CRC) treated with FT836 MICA/B-targeted CAR T with no conditioning chemotherapy.

## SEC filing metadata
- accession: 0001193125-25-279091
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312525279091/0001193125-25-279091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312525279091/fate-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-279091
- JSON: https://secwatch.observer/filing/0001193125-25-279091.json
- Plain text: https://secwatch.observer/filing/0001193125-25-279091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.